Buy Estrolet tablets film-coated 2,5mg N30

Estrolet pills film-coated 2,5mg N30

Condition: New product

1000 Items


More info

Active ingredients


Release form



Letrozole 2.5 mg; Auxiliary substances: magnesium alumometasilicate 10 mg, croscarmellose sodium 3 mg, colloidal silicon dioxide 3 mg, magnesium stearate 0.5 mg, ludipress 81 mg.; Film coating composition: Opadry II yellow 85F32733 (polyvinyl alcohol 35-49%, talc 9.8-25%, macrogol 3350 7.35-35.2%, titanium dioxide and iron oxide yellow (15.15-30%).

Pharmacological effect

Antitumor agent. It is a nonsteroidal aromatase inhibitor, an enzyme that is involved in the synthesis of estrogens in postmenopausal women. Aromatase contributes to the conversion of androgens, synthesized in the adrenal glands (primarily Androstenedione and Testosterone), into estrone and estradiol. The inhibition of aromatase activity is realized by competitive binding to the subunit of this enzyme - the heme of cytochrome P450, which leads to a decrease in the biosynthesis of estrogens in all tissues, including in the tissues of estrogen-dependent tumors.


Treatment of malignant breast tumors in women in the period of natural or artificially induced menopause after anti-estrogen therapy.


Endocrine status characteristic of the premenopausal period; pregnancy; lactation; Hypersensitivity to letrozole.

Use during pregnancy and lactation

Contraindicated in pregnancy, during lactation.

Dosage and administration

The dose is 2.5 mg 1 time per day. Treatment continues during the progression of the disease.

Side effects

Possible: headache, nausea, peripheral edema, general weakness, hot flashes, thinning hair, skin rash, vomiting, dyspepsia, weight gain, musculoskeletal pain, anorexia, vaginal bleeding, leukorrhea, constipation, dizziness, increased appetite, increased sweating ; Rarely: shortness of breath, thrombophlebitis, bloody discharge from the vagina.

special instructions

In patients with QA less than 10 ml / min, the safety of letrozole has not been studied, therefore, if necessary, its use in such cases should carefully weigh the ratio between the expected therapeutic effect and the possible risk of treatment .; Impact on the ability to drive vehicles and other mechanismsrequiring increased concentration; Under the influence of letrozole, the ability to concentrate and the speed of psychomotor reactions may decrease, therefore during the treatment period it is recommended to avoid driving vehicles and other potentially dangerous activities.